Fagron’s share buy-back program: Weekly update

07 Nov 2025 18:39 CET

Issuer

FAGRON S.A.

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 7 November 2025 – 6PM CET

Fagron’s share buy-back program: Weekly update

In the period from 3 November 2025 through 7 November 2025, Fagron purchased 45,000 of its owns shares at an average price of €20.4413 per share corresponding to a total amount of €919,856.70.

These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme, which was announced on 9 October 2025.

The total number of own shares purchased to date is 156,000.

More information, including a detailed overview of the purchase transactions under this program, is available on our share buy-back webpage.

Financial calendar
12 February 2026                Full year results 2025
9 April 2026                         Trading update first quarter 2026
11 May 2026                        Annual General Meeting 2025
30 July 2026                         Half year results 2026
8 October 2026                        Trading update third quarter 2026

Further information
Ignacio Artola
Global Investor Relations Leader
Ignacio.artola@fagron.com

About Fagron

Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 35 countries around the world.

The Belgian company Fagron NV is based on Venecoweg 20A in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV. Fagron BV’s head office is located in Rotterdam.

Important information regarding forward-looking statements
Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment